Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf

The impressive improvement of overall survival in multiple myeloma (MM) patients in the last years has been mostly related to the availability of new classes of drugs with different mechanisms of action, including proteasome inhibitors (PI), immunomodulating agents (IMiDs), and monoclonal antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Barilà, Gregorio, Rizzi, Rita, Zambello, Renato, Musto, Pellegrino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825702/
https://www.ncbi.nlm.nih.gov/pubmed/33430210
http://dx.doi.org/10.3390/ph14010040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825702/
https://www.ncbi.nlm.nih.gov/pubmed/33430210
http://dx.doi.org/10.3390/ph14010040

Ejemplares similares